Eli Lilly Knocks Out Two Teva Migraine Drug Patents at Tribunal

Eli Lilly & Co. succeeded in invalidating two patents asserted in litigation by Teva Pharmaceuticals International GmbH related to its Ajoy migraine drug at a US Patent and Trademark Office administrative tribunal.

Eli Lilly sufficiently demonstrated that US Patent Nos. 11,028,160 and 11,028,161 are unpatentable because they would have been obvious in light of prior art, the Patent Trial and Appeal Board said in two decisions issued Monday.

Calcitonin gene-related peptide “has been found to be involved in migraine processes,” according to the patents, and levels of CGRP are increased during migraine attacks. Inhibition of CGRP or antagonizing CGRP receptor ...